NeuroSense Therapeutics Ltd.
NRSNWDrugs in Pipeline
18
Phase 3 Programs
7
Upcoming Catalysts
2
Next Catalyst
Dec 1, 2026
10wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
citicoline
Stroke
tozuleristide
Pediatric Central Nervous System Tumor
Cerebrolysin
Cadasil
PCV chemotherapy alone
Anaplastic Gliomas With 1p/19q Codeletion
Intensified protocol
Glioblastoma
Ziprasidone
Affective Disorders
Losartan
Newly-diagnosed Glioblastoma
K27M peptide
Diffuse Intrinsic Pontine Glioma
Binimetinib
Neurofibromatosis Type 1
Fixed dose combination Ciprofloxacin/Celecoxib
Amyotrophic Lateral Sclerosis
Cerebrolysin + donepezil
Alzheimer Disease
Panobinostat Nanoparticle Formulation MTX110
Diffuse Intrinsic Pontine Glioma
Paxalisib
Recurrent Atypical Teratoid/Rhabdoid Tumor
Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)
Naive Unresectable Glioblastoma
Chemotherapy Drug, Cancer - Physician's Choice
Embryonal Tumor With Multilayered Rosettes
Huperzine A
Alzheimer Disease
PrimeC
Amyotrophic Lateral Sclerosis
GPI 1485
Impotence
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
citicoline | Phase 3 | Stroke | - | - |
tozuleristide | Phase 3 | Pediatric Central Nervous System Tumor | - | - |
Cerebrolysin | Phase 3 | Cadasil | - | - |
PCV chemotherapy alone | Phase 3 | Anaplastic Gliomas With 1p/19q Codeletion | - | - |
Intensified protocol | Phase 3 | Glioblastoma | - | - |
Ziprasidone | Phase 3 | Affective Disorders | - | - |
Losartan | Phase 3 | Newly-diagnosed Glioblastoma | - | - |
K27M peptide | Phase 2 | Diffuse Intrinsic Pontine Glioma | - | - |
Binimetinib | Phase 2 | Neurofibromatosis Type 1 | - | - |
Fixed dose combination Ciprofloxacin/Celecoxib | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Cerebrolysin + donepezil | Phase 2 | Alzheimer Disease | - | - |
Panobinostat Nanoparticle Formulation MTX110 | Phase 2 | Diffuse Intrinsic Pontine Glioma | - | - |
Paxalisib | Phase 2 | Recurrent Atypical Teratoid/Rhabdoid Tumor | - | - |
Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures) | Phase 2 | Naive Unresectable Glioblastoma | - | - |
Chemotherapy Drug, Cancer - Physician's Choice | Phase 2 | Embryonal Tumor With Multilayered Rosettes | - | - |
Huperzine A | Phase 2 | Alzheimer Disease | - | - |
PrimeC | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
GPI 1485 | Phase 2 | Impotence | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NeuroSense Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in NeuroSense Therapeutics Ltd.'s (NRSNW) pipeline across Phase 3, Phase 2. Its lead program is citicoline (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NeuroSense Therapeutics Ltd.'s next FDA catalyst?→
NeuroSense Therapeutics Ltd.'s (NRSNW) next tracked catalyst is a Regulatory expected December 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NRSNW biotech catalysts?→
Add NRSNW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NeuroSense Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.